Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-07-18
2006-07-18
Borin, Michael (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S037000, C424S094630, C435S183000, C435S220000
Reexamination Certificate
active
07078377
ABSTRACT:
Co-administration of a lysostaphin or other anti-staphylococcal agent which cleaves cross-links of peptidoglycans of staphylococci cell walls such as lysostaphin and an antibiotic effective against staphylococci due to antibiotic activity mediated by cell-wall activity is effective against staphylococcal infection, even staphylococci that may be resistant to one or other of lysostaphin or the cell-wall active antibiotic. Co-administration simultaneously suppresses the generation of antibiotic-resistant mutant strains. Effective cell-wall active antibiotics include β-lactams and glycopeptides.
REFERENCES:
patent: 3278378 (1966-10-01), Schindler et al.
patent: 3398056 (1968-08-01), Zygmunt et al.
patent: 3594284 (1971-07-01), Zygmunt et al.
patent: 4931390 (1990-06-01), Recsei
patent: 5760026 (1998-06-01), Blackburn et al.
patent: 5858962 (1999-01-01), Blackburn et al.
patent: 6028051 (2000-02-01), Climo et al.
Moreira B. et al. Antimicrobial Agents and Chemotherapy, (Aug. 1997) 41 (8) 1788-93.
Database Medline, DN 69:25280 Pulverer et al. Z. Med. Mikrobiol. Immunol. (1968), 154(1), 40-8.
Database Medline, DN 81:163936 Chopra et al. J. Gen. Microbiol. (1974), 82, Pt. 2, 419-20.
Chambers, Henry F., “Parenteral Antibiotics for the Treatment of Bacteremia and Other Serious Staphylococcal Infections”, The Staphylococci in Human Disease, Chapter 26, pp. 583-595 (1997).
Polak, et al., “In Vitro Activity of Recombinant Lysostaphin-Antibiotic Combinations Toward Methicillin-ResistantStaphylococcus aureas”, Diagn Microbiol Infect Dis, 17:265-270 (1993).
Berger-Bächi, Brigitte, “Resistance Not Mediated By β-Lactamase (Methicillin Resistance)”, The Staphylococci in Human Disease, Grassley, et al. (eds), Chapter 6 (part 2), pp. 158-174 (1997).
Tschierske, et al., “Lif, the Lysostaphin Immunity Factor, Complements FemB in Staphylococcal Peptidoglycan Interpeptide Bridge Formation”, FEMS Microbiology Letters, vol. 153, pp. 261-264 (1997).
DeHart, et al., “The Lysostaphin Endopeptidase Resistance Gene (epr) Specifies Modification of Peptidoglycan Cross Bridges inStaphylococcus simulansandStaphylococcus aureus”, Applied and Environmental Microbiology, vol. 61, No. 4, pp. 1475-1479, Apr. 1995.
Strandén, et al., “Cell Wall Monoglycine Cross-Bridges and Methicillin Hypersusceptibility in a femAB Null Mutant of Methicillin-ResistantStaphylococcus aureus”, Journal of Bacteriology, vol. 179, No. 1, pp. 9-16, Jan. 1997.
Zygmunt, et al., “Lytic Action of Lysostaphin on Susceptible and Resistant Strains ofStaphylococcus aureus”, Canadian Journal of Microbiology, vol. 13, pp. 845-853 (1967).
Ehlert, et al., “Specificities of FemA and FemB for Different Glycine Residues: FemB Cannot Substitute for FemA in Staphylococcal Peptidoglycan Pentaglycine Side Chain Formation”, Journal of Bacteriology, vol. 179, No. 23, pp. 7573-7576 (Dec. 1997).
Dixon, et al., “Lysostaphin: An Enzymatic Approach to Staphylococcal Disease. III. Lystostaphin-Methicillin Therapy of Established Staphylococcal Abcesses in Mice”, Yale Journal of Biology and Medicine, vol. 41, pp. 62-68, Aug. 1968.
Schaffner, et al., “Lysostaphin: An Enzymatic Approach to Staphylococcal Disease. II. Lysostaphin, in vivo Studies”, Yale Journal of Biology and Medicine, vol. 39, pp. 230-244, Feb. 1967.
Schaffner, et al., “Lysostaphin: An Enzymatic Approach to Staphylococcal Disease. I. Lysostaphin in vitro Studies”, Yale Journal of Biology and Medicine, vol. 39, pp. 215-229, Feb. 1967.
Kessler, et al., “Secreted LasA ofPseudomonas aeruginosaIs a Staphylolytic Protease”, The Journal of Biological Chemistry, vol. 268, No. 10, pp. 7503-7508 (1993).
Li, et al., “Purification, Staphylolytic Activity, and Cleavage Sites of α-Lytic Protease fromAchromobacter lyticus”, The Journal of Biological Chemistry, vol. 122, No. 4, pp. 772-778 (1997).
Oldham, et al., “Lysostaphin: Use of a Recombinant Bactericidal Enzyme as a Mastitis Therapeutic”, J. Diary of Sci., 74:4175-4182 (1991).
Martin, et al., “The Selective Activity of Lysotaphin in vivo”, The Journal of Laboratory and Clinical Medicine, vol. 70, No. 1, pp. 1-8 (Jul. 1967).
Martin, et al., “The Reacquisition of Staphylococci by Treated Carriers: A Demonstration of Bacterial Interference”, J. Lab. Clin. Med., vol. 71, No. 5, pp. 791-797 (May 1968).
Harrison et al., “Therapeutic Activity of Lysostaphin in Experimental Staphylococcal Infections”, Canadian Journal of Microbiology, vol. 13, pp. 93-97 (1967).
Schuhardt, et al., “Lysostaphin Therapy in Mice Infected withStaphylococcus aureus”, J. Bacteriol., vol. 88, No. 1064, pp. 815-816.
Harrison, et al., “Lysostaphin in Experimental Renal Infections”, Journal of Bacteriology, pp. 520-524, (Feb. 1967).
Stark, et al., “Systemic Lysostaphin Man—Apparent Antimicrobial Activity in A Neutropenic Patient”, The New England Journal of Medicine, pp. 239-240 (Aug. 1974).
Goldberg et al., “Studies in Experimental Staphylococcal Endocarditis in Dogs. VI. Treatment in Lysostaphin”, Antimicrobial Agents and Chemotherapy, pp. 45-53 (1967).
Quickel, Jr. et al, “Efficacy and Safety of Topical Lysostaphin Treatment of Persistent Nasal Carriage ofStaphylococcus aureus”, Applied Microbiology, pp. 446-450 (Sep. 1971).
Archer Gordon
Climo Michael
Murphy Ellen
Borin Michael
Kelber Steven B.
Merchant & Gould P.C.
Nutrition 21, Inc.
LandOfFree
Compositions and methods for treatment of staphylococcal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treatment of staphylococcal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of staphylococcal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3543020